Silence Therapeutics plc ADR (SLN)
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production.
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full detailed results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, are to be presented at an upcoming medical conference before the end of 2024.
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD.
